Health Blueprint

Back to Longevity News

News summary

Metabolize raises $3.2 million for consumer metabolic-health products

Source: BioSpace - Funding • Published: 15 Oct 2026, 11:32

Summarized by Masters of Longevity from BioSpace - Funding.

Astanor led the seed round, with proceeds supporting product development, validation, manufacturing and a planned January 2027 launch of NATLEAN.

Metabolize raises $3.2 million for consumer metabolic-health products
Key Takeaways
  • The company plans to market NATLEAN for people transitioning off GLP-1 therapies.
  • The financing supports products based on licensed Stanford-originated research.
  • The release provides no clinical evidence that NATLEAN can prevent weight regain.
Read the full article at BioSpace - Funding ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickFrom Metrics to Better LivingEverstride’s May 2026 Consumer Health Market Briefing shows a wellness market moving from products to systems, from tracking to guidance, and from optimization to meaning. The next winners in longevity may not be the companies that measure the most. They may be the ones that help consumers translate health data into a life they actually want to live.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?